Aplastic anemia is a marrow-failure syndrome, not one abnormal count
Aplastic anemia causes low red cells, white cells and platelets because marrow production is markedly reduced. Diagnosis requires marrow examination and exclusion of leukemia, MDS, inherited marrow failure, medicines, toxins, infection and other causes.
Severity, age, donor availability, comorbidities and local expertise shape the choice between allogeneic transplant and immunosuppressive therapy. Supportive transfusion and infection management begin immediately when needed.
Flow, cytogenetic, molecular, PNH and inherited testing may be needed to distinguish overlapping conditions and guide long-term monitoring.
Who may be considered?
Specialist review may help when the source diagnosis and treatment timeline raise a practical question about marrow-failure diagnosis and treatment.
- Pancytopenia with a hypocellular marrow.
- Severe or very severe aplastic anemia needing urgent pathway selection.
- A younger patient with a possible matched donor.
- Persistent disease or relapse after immunosuppression.
- A case with PNH clone, cytogenetic change or inherited-disease concern.
What the specialist team must confirm
The team reviews serial counts, reticulocytes, marrow cellularity and morphology, cytogenetics, molecular and PNH testing, viral and immune evaluation, medication and exposure history, inherited features, HLA typing, infections, bleeding and transfusion history.
Key points for this treatment
From pancytopenia to marrow-restoration strategy
Severity and donor status guide the branch, while supportive care protects the patient during decision and response time.
Response monitoring and clonal surveillance
Response to immunosuppression can take time, so transfusion needs, infections and count trends are followed while avoiding premature conclusions.
Long-term monitoring checks relapse, PNH evolution and clonal progression. Transplant may be reconsidered when response is inadequate or disease changes.
Limits, burdens and realistic expectations
Severe infection or bleeding can occur before treatment works. Immunosuppression may not produce durable recovery and can be followed by relapse or clonal disease. Transplant has GVHD, infection, infertility and treatment-related mortality risks.
Fever, uncontrolled bleeding, new severe headache, breathlessness, fainting or rapidly worsening weakness requires emergency local care.